Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for bioAffinity Technologies, Inc. (BIAF : NSDQ)

• Company Description    bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $1.56 Daily Weekly Monthly 20 Day Moving Average: 365,196 shares Shares Outstanding: 4.53 (millions) Market Capitalization: $7.07 (millions) Beta: -1.19 52 Week High: $15.00 52 Week Low: $0.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.17% -35.49% 12 Week 50.00% 38.67% Year To Date 32.20% 26.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 NACOGDOCHES ROAD SUITE 216 - SAN ANTONIO,TX 78217 USA ph: 210-698-5334 fax: - biaf@redchip.com http://www.bioaffinitytech.com

• General Corporate Information    Officers Maria Zannes - President; Chief Executive Officer; and Director Steven Girgenti - Executive Chairman and Director J. Michael Edwards - Chief Financial Officer Robert Anderson - Director John Oppenheimer - Director Peer Information bioAffinity Technologies, Inc. (CORR.) bioAffinity Technologies, Inc. (RSPI) bioAffinity Technologies, Inc. (CGXP) bioAffinity Technologies, Inc. (BGEN) bioAffinity Technologies, Inc. (GTBP) bioAffinity Technologies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09076W307 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 4.53 Most Recent Split Date: 9.00 (0.03:1) Beta: -1.19 Market Capitalization: $7.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.93 Price/Cash Flow: - Price / Sales: 1.25 EPS Growth vs. Year Ago Period: 83.14% vs. Previous Quarter: 27.03% Sales Growth vs. Year Ago Period: -27.08% vs. Previous Quarter: -15.13% ROE 03/31/26 - -285.75 12/31/25 - -301.67 09/30/25 - -425.87 ROA 03/31/26 - -143.71 12/31/25 - -142.38 09/30/25 - -162.30 Current Ratio 03/31/26 - 1.36 12/31/25 - 2.60 09/30/25 - 3.65 Quick Ratio 03/31/26 - 1.34 12/31/25 - 2.58 09/30/25 - 3.64 Operating Margin 03/31/26 - -223.42 12/31/25 - -189.47 09/30/25 - -169.76 Net Margin 03/31/26 - -280.53 12/31/25 - -241.93 09/30/25 - -217.45 Pre-Tax Margin 03/31/26 - -279.90 12/31/25 - -241.25 09/30/25 - -216.86 Book Value 03/31/26 - 0.81 12/31/25 - 1.62 09/30/25 - 1.98 Inventory Turnover 03/31/26 - 71.93 12/31/25 - 98.57 09/30/25 - 134.32 Debt-to-Equity 03/31/26 - 0.15 12/31/25 - 0.08 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 13.14 12/31/25 - 7.31 09/30/25 - 0.51

Powered by Zacks Investment Research ©